Fukuda Denshi Co Ltd (Fukuda Denshi) develops, distributes, and commercializes medical engineering devices. The company's product portfolio includes electrocardiographs, patient monitoring systems, and other healthcare technologies. Fukuda Denshi offers prevention/testing, treatment, follow-up observation, home medical care, and rehabilitation.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

The company focuses its research and development initiatives on devices for examining, diagnosing, and treating respiratory and circulatory system diseases, particularly electrocardiogram-related devices such as electrocardiographs. The company also develops vital signs monitors, defibrillators, and oxygen concentrators, along with bioelectrodes and sensors used with these devices. The R&D activities are aligned with the company's management philosophy of contributing to medical advancements through the development of medical electronics equipment and adapting to user needs. The company is developing CAVI parameter of the VaSera series, that is appropriate for predicting cardiovascular events. The digital Holter ECG Recorder, FM-180, has been used for medical experiments. The company considers M&A to further reinforce its R&D. The company also aims to establish AI and robotics for more innovative technology. In FY2025, the company spent JPY4,221 million on its R&D activities, which decreased 10.9% YoY.